Business Context and Reporting Period
This Form 20-F is the annual report for Amarin Corporation plc for the fiscal year ended December 31, 2003. Amarin is an emerging drug development company focused on neuroscience, specifically the development of LAX-101 for Huntington's disease. During 2003 and early 2004, the company underwent a significant strategic transformation, divesting its commercial operations (Amarin Pharmaceuticals Inc. and Amarin Development AB) to transition from a commercial pharmaceutical entity to a development-stage company. The company changed its functional currency from pounds sterling to US dollars effective January 1, 2003.
Key Financial Metrics
Financial data is presented in thousands of US dollars, except per share data. The company reported losses under both UK GAAP and US GAAP.
| Metric | 2003 (UK GAAP) | 2003 (US GAAP) | 2002 (UK GAAP) |
|---|---|---|---|
| Total Revenues | $7,365 | $2,790 | $65,441 |
| Operating Loss | $(38,821) | $(25,841) | $(32,630) |
| Net Loss | $(19,224) | $(28,436) | $(37,047) |
| Net Loss Per Share (Basic) | $(1.12) | $(1.66) | $(3.98) |
| Cash and Cash Equivalents (Year End) | $2,097 | $2,097 | $24,265 |
| Total Debt (Year End) | $31,500 | $31,500 | $42,500 |
| Shareholders' Equity (Deficit) | $(6,348) | $(10,552) | $(6,208) |
Note: Revenues and Net Loss figures differ significantly between UK GAAP and US GAAP due to the classification of discontinued operations and accounting treatment of intangible assets.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues dropped from $65.4 million in 2002 to $7.4 million in 2003 (UK GAAP). This 89% decline is primarily due to the classification of the US commercial business (API) and Swedish development business (ADAB) as discontinued operations. Continuing operations revenue was negligible at $0.1 million.
- Discontinued Operations: The 2003 results include significant charges related to discontinued operations, including $9.0 million in charges for Permax returns and inventory risks due to generic competition, and $5.3 million in inventory provisions.
- Asset Divestitures: In October 2003, the company sold its Swedish subsidiary (ADAB) to Watson Pharmaceuticals for approximately $15 million. In February 2004 (post-year-end), the company sold its US subsidiary (API) and product portfolio (including Permax and Zelapar) to Valeant Pharmaceuticals for approximately $46 million.
- Debt Restructuring: The company renegotiated significant debt obligations with Elan Corporation plc. As of December 31, 2003, debt totaled $31.5 million. In February 2004, this was settled via cash payments and the issuance of a new $5 million loan note and warrants.
Guidance, Outlook, and Risks
Outlook: Following the divestitures, Amarin has no marketable products and relies on the development of LAX-101, a Phase III candidate for Huntington's disease. The company expects to fund operations through March 31, 2005, based on cash balances as of March 24, 2004 ($10.7 million). Future revenues are contingent upon the successful development and regulatory approval of LAX-101 or the acquisition of new products.
Management Commentary: Management states that historical financial results do not form an accurate basis for assessing the current business due to the divestiture of the majority of assets. The company is now a development-stage entity with limited operations.
Risks and Contingencies:
- Capital Needs: The company requires additional capital to fund LAX-101 development and future acquisitions. Failure to raise capital could force a cessation of operations.
- Single Product Reliance: The business is heavily dependent on the success of LAX-101. Failure in clinical trials or regulatory approval would materially harm the company.
- Licensing Risks: Amarin relies on Laxdale Limited to fund and conduct clinical trials for LAX-101. Laxdale's financial stability and the death of its founder in 2003 present uncertainties.
- Nasdaq Listing: The company does not meet Nasdaq's minimum stockholders' equity requirement of $10 million. It is working on a plan to regain compliance, but delisting remains a risk.
- Legal Proceedings: There are potential product liability claims related to Permax (valvular heart disease), though the company sold the product and related liabilities to Valeant. There is also a dispute regarding a $6 million inventory adjustment with Valeant post-closing.
Important Facts for Investor Verification
- Post-Year-End Transactions: Verify the final terms and closing of the API sale to Valeant (Feb 2004) and the debt settlement with Elan, as these fundamentally altered the company's balance sheet and future obligations.
- LAX-101 Development Status: Confirm the current status of the Phase III trials for LAX-101 and the financial capability of the licensor, Laxdale Limited, to fund them.
- Liquidity Position: Assess the company's cash runway and ability to raise additional equity or debt financing given its negative equity position and lack of current revenue.
- Nasdaq Compliance: Monitor the company's progress in meeting Nasdaq listing requirements to avoid delisting.
- GAAP Differences: Note the significant differences between UK GAAP and US GAAP reporting, particularly regarding the classification of discontinued operations and the treatment of intangible assets.